EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The future of pharmaceuticals: Artificial intelligence in drug discovery and development

Chen Fu, Qiuchen Chen

Journal of Pharmaceutical Analysis · 2025-08 · 15 (8) · 101248

DOI: 10.1016/j.jpha.2025.101248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2025-08. Verfasst von Chen Fu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China. Die Arbeit wurde bisher 149-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Department of Education of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial Intelligence (AI) is revolutionizing traditional drug discovery and development models by seamlessly integrating data, computational power, and algorithms. This synergy enhances the efficiency, accuracy, and success rates of drug research, shortens development timelines, and reduces costs. Coupled with machine learning (ML) and deep learning (DL), AI has demonstrated significant advancements across various domains, including drug characterization, target discovery and validation, small molecule drug design, and the acceleration of clinical trials. Through molecular generation techniques, AI facilitates the creation of novel drug molecules, predicting their properties and activities, while virtual screening (VS) optimizes drug candidates. Additionally, AI enhances clinical trial efficiency by predicting outcomes, designing trials, and enabling drug repositioning. However, AI's application in drug development faces challenges, including the need for robust data-sharing mechanisms and the establishment of more comprehensive intellectual property protections for algorithms. AI-driven pharmaceutical companies must also integrate biological sciences and algorithms effectively, ensuring the successful fusion of wet and dry laboratory experiments. Despite these challenges, the potential of AI in drug development remains undeniable. As AI technology evolves and these barriers are addressed, AI-driven therapeutics are poised for a broader and more impactful future in the pharmaceutical industry.

Schlagwörter

Stichwörter der Autor:innen

AIDrugsMachine learningResearch and development

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China.
  • Pharmaceutical Sciences Laboratory Center, School of Pharmacy, China Medical University, Shenyang, 110122, China.
  • Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, China.

Förderung

  • National Natural Science Foundation of China
  • Department of Education of Liaoning Province

Zitieren

APA

Fu, C., & Chen, Q. (2025). The future of pharmaceuticals: Artificial intelligence in drug discovery and development. Journal of Pharmaceutical Analysis, 15(8), 101248. https://doi.org/10.1016/j.jpha.2025.101248

Vancouver

Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. Journal of Pharmaceutical Analysis. 2025;15(8):101248. doi:10.1016/j.jpha.2025.101248

BibTeX
@article{Fu2025,
  author = {Fu, Chen and Chen, Qiuchen},
  title = {The future of pharmaceuticals: Artificial intelligence in drug discovery and development},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {101248},
  doi = {10.1016/j.jpha.2025.101248}
}
Kostenlos starten →